Intas is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $8.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Intas's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Rinvoq | AbbVie | Generic | 2037 | Settled Sep 2025 | $8.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Intas's share of it.